Italian maker of glass vials, syringes and drug-containment/delivery systems for the pharmaceutical and biotech industry.
Italian maker of glass vials, syringes and drug-containment/delivery systems for the pharmaceutical and biotech industry.
Sells containers by the unit to drugmakers, and orders recur as customers fill batches of their drugs, so demand follows their injectable volumes. A founding family controls it through a holding company. Engineering sales of machines used on packaging lines are lumpier, project-style business.
Moat: narrow (customer qualification, IP / patents, switching costs). Packaging components are qualified in customers' regulatory drug filings, making switching costly and slow.
Headquarters: Piombino Dese, Italy · Founded: 1949
Size Stevanato (STVN) is a United States Health Care company (Medical Specialties) with a market value of $4.19B, the 1303rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $15.36 on 18 Nov 2026.
Performance Over six months the shares fell 13.5%, against +29.6% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 12.0% over the last twelve months (peer median +8.3%); the operating margin is 17.6% (peer median 13.1%).
Valuation It trades at 22.5× forward earnings against a peer median of 20.2× (7th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.4 points above its cost of capital (8.7% WACC).
Short interest Short interest is 1.8% of the free float (30 Oct 2026).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.45B | $1.34B | $1.19B | $1.17B | $1.03B |
| Revenue growth | — | +12% | +2% | +14% | — |
| Gross profit | $418M | $375M | $316M | $353M | $324M |
| EBITDA | $369M | $315M | $252M | $291M | $251M |
| Net income | $163M | $158M | $127M | $157M | $150M |
| Free cash flow | $14.4M | $25.2M | -$159M | -$355M | -$138M |
| Capital expenditure | $308M | $310M | $339M | $478M | $256M |
| Total debt | $533M | $551M | $444M | $440M | $233M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Stevanato STVN | $4.19B | -13% | +12% | 18% | 22.5× | 13.1% |
| West Pharmaceutical Services WST | $28.1B | +32% | +13% | 23% | 40.2× | 25.8% |
| Gerresheimer GXI.DE | $1.26B | +21% | +9% | -4% | 16.0× | 57.0% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | $3.73B | +32% | +4% | 15% | 23.0× | 12.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | STVN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.2% | +5.2% | lowest of 21 |
| 6-month return | -13.5% | +29.6% | 2nd lowest of 21 |
| Distance from 52-week high | -36.0% | -18.0% | 4th lowest of 21 |
| Revenue growth (TTM) | +12.0% | +8.3% | 8th highest of 21 |
| Operating margin | 17.6% | 13.1% | 4th highest of 20 |
| Forward P/E | 22.5× | 20.2× | 7th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 13.1% | 9.3% | 6th most demanding of 17 |
| Growth delivered (Del g) | +12.1% | +8.2% | 2nd highest of 17 |
| Hurdle (Req g minus delivered) | +1.0 pp | +1.6 pp | 8th least demanding of 17 |
| ROIC minus cost of capital | +0.4 pp | +1.5 pp | 8th lowest of 19 |
| EV / EBITDA | 12.5× | 13.3× | 6th cheapest of 13 |
| Net debt / EBITDA | 1.1× | 0.1× | 4th most indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Stevanato STVN | United States | $4.19B | -13% | +12% | 18% | 22.5× | 13.1% | +12.1% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.18B | -3% | -1% | 13% | 20.0× | 4.9% | +3.4% |
| ICU Medical ICUI | United States | $4.46B | +38% | -6% | 8% | 19.4× | 18.9% | +11.9% |
| Fielmann FIE.DE | Germany | $3.92B | -3% | +3% | 14% | 17.1× | -5.5% | +11.3% |
| CareDx CDNA | United States | $3.91B | +252% | +39% | 1% | 50.6× | n/a | n/a |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% | -7.4% |
| GRAIL GRAL | United States | $4.59B | +67% | +17% | -332% | n/a | n/a | n/a |
| Envista NVST | United States | $3.81B | 0% | +10% | 12% | 14.7× | 4.8% | +7.1% |
| Sotera Health SHC | United States | $4.65B | +5% | +7% | 37% | 15.7× | 14.4% | +7.3% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.73B | +32% | +4% | 15% | 23.0× | 12.7% | +11.0% |
| MiniMed MMED | United States | $4.78B | +46% | +14% | 14% | 26.3× | n/a | n/a |
| DiaSorin DIA.MI | Italy | $4.81B | +24% | -3% | 24% | 20.5× | 4.1% | +6.3% |
| Intco Medical Technology 300677.SZ | China | $4.82B | -2% | +33% | 20% | 18.5× | -3.5% | -6.4% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -1% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| Tecan TECN.SW | Switzerland | $3.60B | +59% | -4% | 1% | 35.5× | 45.4% | +3.8% |
| Sumitomo Bakelite 4203.T | Japan | $3.50B | +7% | +15% | 13% | 15.9× | 8.6% | +8.9% |
| Ambu A/S AMBU-B.CO | Denmark | $3.47B | +31% | +7% | 13% | 28.8× | 10.0% | +10.0% |
| Merit Medical Systems MMSI | United States | $5.15B | +33% | +9% | 14% | 19.1× | 12.6% | +9.5% |
| Axogen AXGN | United States | $3.40B | +33% | +24% | -5% | 87.3× | 52.6% | +14.9% |
| LivaNova LIVN | United States | $5.21B | +28% | +12% | 15% | 20.9× | 14.2% | +8.2% |
| Pulse Biosciences PLSE | United States | $3.37B | +76% | +1,637% | -5,821% | n/a | n/a | n/a |